Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options.
about
Defective calcium inactivation causes long QT in obese insulin-resistant ratInsulin resistance and hyperinsulinaemia in diabetic cardiomyopathyInsulin resistance protects the heart from fuel overload in dysregulated metabolic statesOptimization of cardiac metabolism in heart failureTargeting myocardial substrate metabolism in heart failure: potential for new therapiesCardiometabolic Syndrome and Increased Risk of Heart FailureDiabetic cardiomyopathy: signaling defects and therapeutic approachesHyperglycemia and hyperlipidemia blunts the Insulin-Inpp5f negative feedback loop in the diabetic heartAssociation of genome-wide variation with the risk of incident heart failure in adults of European and African ancestry: a prospective meta-analysis from the cohorts for heart and aging research in genomic epidemiology (CHARGE) consortiumTRB3 gene silencing alleviates diabetic cardiomyopathy in a type 2 diabetic rat modelBayesian parameter estimation for characterizing the cyclic variation of echocardiographic backscatter to assess the hearts of asymptomatic type 2 diabetes mellitus subjects.Quantitative analysis of the magnitude and time delay of cyclic variation of myocardial backscatter from asymptomatic type 2 diabetes mellitus subjects.Effects of metformin and exercise training, alone or in association, on cardio-pulmonary performance and quality of life in insulin resistance patientsDiabetic cardiomyopathy: where we are and where we are going.Glucose, obesity, metabolic syndrome, and diabetes relevance to incidence of heart failure.Decreased long-chain fatty acid oxidation impairs postischemic recovery of the insulin-resistant rat heart.Impact of metabolic syndrome on global left ventricular function: As evaluated by the myocardial performance index.Association between prehypertension, metabolic and inflammatory markers, decreased adiponectin and enhanced insulinemia in obese subjects.The early origins of chronic heart failure: impaired placental growth and initiation of insulin resistance in childhood.Exenatide improves glucose homeostasis and prolongs survival in a murine model of dilated cardiomyopathy.Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research DatabaseMyocardial insulin resistance induced by high fat feeding in heart failure is associated with preserved contractile function.T(-786)→C polymorphism of the endothelial nitric oxide synthase gene is associated with insulin resistance in patients with ischemic or non ischemic cardiomyopathyThe critical role of Astragalus polysaccharides for the improvement of PPARα [ correction of PPRAα]-mediated lipotoxicity in diabetic cardiomyopathyRelations of insulin resistance and glycemic abnormalities to cardiovascular magnetic resonance measures of cardiac structure and function: the Framingham Heart Study.Unrecognized glucose intolerance is common in pulmonary arterial hypertensionApolipoprotein A-I mimetic peptide L-4F prevents myocardial and coronary dysfunction in diabetic mice.Diabetic cardiac autonomic neuropathy: Do we have any treatment perspectives?Short-chain fatty acid propionate alleviates Akt2 knockout-induced myocardial contractile dysfunction.Role of oxidative stress in disease progression in Stage B, a pre-cursor of heart failure.Altered systemic ketone body metabolism in advanced heart failure.Murine hyperglycemic vasculopathy and cardiomyopathy: whole-genome gene expression analysis predicts cellular targets and regulatory networks influenced by mannose binding lectinMetabolic stress-induced activation of FoxO1 triggers diabetic cardiomyopathy in mice.Transition from obesity to metabolic syndrome is associated with altered myocardial autophagy and apoptosis.Emerging beneficial roles of sirtuins in heart failure.From NAFLD to Cardiovascular Disease. Is it (Still) the Metabolic Syndrome?Emerging role of liver X receptors in cardiac pathophysiology and heart failure.A personalized BEST: characterization of latent clinical classes of nonischemic heart failure that predict outcomes and response to bucindolol.Sustained βAR Stimulation Mediates Cardiac Insulin Resistance in a PKA-Dependent Manner.Effects of analogue insulin in multiple daily injection therapy of type 2 diabetes on postprandial glucose control and cardiac function compared to human insulin: a randomized controlled long-term study.
P2860
Q23924028-A42C998F-D658-4566-9558-385B777A401BQ26775037-4D995B62-FE47-4AB6-BE5B-6C016B480162Q26829463-79A09E89-CE82-4F74-B72E-734C496FCFE5Q27023021-D08A9D60-7A51-4D89-A156-B3F292C3925EQ27694733-C3F6AA6D-9C07-44E6-9F2E-4B0C8664723AQ28070075-2E35E556-A672-478D-B317-31328077703AQ28395852-D9CF18D6-7515-4FCC-8FAD-E7D7CC141375Q28583594-3B22D28E-F60E-4D07-A921-613481C94BB6Q28943463-D009D4F8-83A3-4834-A5D3-1609B7B5AD34Q30461459-7BD63A4A-9691-4A38-A798-4263FF167D33Q30468216-10E74311-B62C-48EB-B304-8A24A66743EFQ30479827-358056F1-A121-4689-A3B9-1A13A6C64FDBQ33647988-D36D9E77-D7EC-4B94-B5C6-CA84327B6FD9Q33690717-4E3503E5-E522-4A8F-A06F-6A2DFF0D0655Q33710663-14FAA7BF-539B-47E4-BB2D-AA8962202DC6Q33713702-6D91F9B6-1B6E-4138-AEE0-A51A12FB5F47Q33774849-D0C0EC49-6339-4860-906C-0037E61EE235Q33803656-EC77E416-9248-4712-A2A5-018837207EA3Q33816674-15EDD5FB-6E17-43BC-A0E5-EE98541458A6Q33832036-1304A1E6-55FB-4435-9033-E1A1566E46C3Q33873040-C863481A-AC6C-4143-8C65-470796F397DDQ34426167-39DE9BC9-7DF0-4C63-8BAA-860B267EB1E9Q34432220-9B4C24EE-446A-4F80-A400-EC0B6E434D42Q34437557-F6D985DD-ECA1-4C65-80F4-F44347025977Q34670148-6CF66F17-578E-4400-A6CF-E2D9FB8A41CFQ35085796-78DEFA60-EFBC-437F-A4FF-FD35EF4E3F78Q35172781-287DE9E1-992D-4D4A-AF0A-373AB99FF047Q35179226-EB037096-AA37-493E-9578-1401F967645EQ35231890-789CCE56-675E-45B0-A198-6320D2137D16Q35581462-997EF528-8126-47B7-91A8-4DEBAC88EAA7Q35594825-9431AF88-811E-4C00-B0D8-183C5087ADC6Q35777842-EB7475FB-A922-4731-A897-55E18424DEDFQ35780290-40B6EDB8-6D14-4338-B1E8-D3B7F27B6C40Q35903265-4F0C3336-B8C2-4414-A325-64B38B3E8AE4Q36078945-F7B0850B-661A-448E-98BB-DF9ABD077410Q36207195-5EF01110-7271-4320-8B04-25790D85DA76Q36322805-FB426E0B-5EC6-46BD-82E1-03082ABED7F5Q36380826-4288AF15-BD4D-4134-A37A-29469898C899Q36415798-E520D4D0-6210-4C1E-A0CD-751E6EB20DECQ36469075-5A9EE9C4-25CD-4502-83B7-38883E24F50A
P2860
Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options.
@en
Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options.
@nl
type
label
Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options.
@en
Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options.
@nl
prefLabel
Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options.
@en
Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options.
@nl
P1476
Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options.
@en
P2093
Michael B Fowler
Ronald M Witteles
P304
P356
10.1016/J.JACC.2007.10.021
P407
P577
2008-01-01T00:00:00Z